With Leadership Changes On The Horizon, Chinese Vice Premier Sheds Light On Future Of China Healthcare Reform
This article was originally published in PharmAsia News
Analysts predict that healthcare reforms will continue and that major policy changes are unlikely during the leadership transition, which starts next year.
You may also be interested in...
HONG KONG - Rising labor costs are putting stress on manufacturing operations in China, but may prove to be a boon in the long term for companies focused on the world's fastest-growing domestic market
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.